Full Press Release Details
Sensus Healthcare Reports Fourth Quarter
and Full Year 2016 Results
Revenues of $4.9 million in Fourth Quarter
revenues increased 44% year-over-year to $14.8 million
- Worldwide installed
base increased to 271 units
BOCA RATON, Fla., Feb. 2, 2017 /PRNewswire/
- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and
other skin conditions, such as keloids, with superficial radiation therapy (SRT), today reported its financial results for the
three-month period and full year ended December 31, 2016.
Recent Business Highlights
"Throughout 2016, Sensus Healthcare achieved numerous
corporate milestones including the completion of our Initial Public Offering, the continued acceptance and utilization of our proprietary
SRT technology by physicians and patients, alike, and the strengthening of our rapidly growing sales team," noted Joseph
Sardano, President and CEO of Sensus Healthcare. "I am equally delighted to report
a tremendous close to 2016, highlighted by our best fourth quarter results ever with revenues of $4.9 million which represented
the fifth consecutive quarter of significant year-over-year revenue growth for Sensus Healthcare, setting the stage for continued
momentum and growth. For the full year 2016, we achieved $14.8 million in revenue, an increase of 44% compared to $10.3 million
Mr. Sardano continued, "We remain focused on our mission
to provide a non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. We are also dedicated to exploring
innovative ways SRT technology can be used as an alternative to current treatments for other skin disorders."
Q4 2016 Financial Highlights
Revenues for Q4 2016 increased 27% to $4.88 million,
compared to $3.84 million for Q4 2015. This increase was the result of increased unit sales, including a strong contribution to
sales from the SRT-100 Vision systems, which has a higher average selling price.
Gross Margin for Q4 2016 was 68.5%, compared to 62.8%
for Q4 2015. Gross margins were positively affected by strong sales of the higher priced, higher margin SRT-100 Vision systems.
Selling and Marketing Expenses for Q4 2016 were $1.67
million, compared to $1.15 million in Q4 2015. This increase was the result of increased headcount of the sales team as well as
increased advertising and other marketing costs.
General and Administrative Expenses for Q4 2016 were
$0.92 million, compared to $0.51 million in Q4 2015. This increase was primarily related to public company expenses. In 2016, the
company incurred expenses attributable to becoming a public company in June 2016.
Research and Development Expenses for Q4 2016 were $0.73
million, compared to $0.33 million in Q4 2015. This increase was primarily due to new research projects that began in Q4 2016.
GAAP Net Income Attributable to Common Stockholders for
Q4 2016 was $0.03 million, or $0.00 per share, compared to a net income attributable to common stockholders of $0.29 million, or
$0.03 per share for Q4 2015. The net income attributable to common stockholders for Q4 2015 included a non-cash accounting charge
of approximately $0.13 million for a preferential distribution attributable to preferred stockholders prior to the IPO.
Adjusted EBITDA for Q4 2016 was $0.21 million, compared
to $0.49 million for Q4 2015. Adjusted EBITDA is defined as earnings before depreciation and amortization, income taxes, interest
expense, stock compensation expense and litigation settlement expense. Please see below for a reconciliation between GAAP and non-GAAP
financial measures, and the specific reasons these non-GAAP financial measures are provided.
Cash, Cash Equivalents and Investments were $12.6 million
as of December 31, 2016.
Full Year 2016 Financial Highlights
Revenues for the full year ended December 31, 2016 increased
44% to $14.81 million, compared to $10.27 million for same period in 2015. This increase was primarily the result of increased
unit sales, with a strong contribution to sales from the SRT-100 Vision product, which has a higher average selling price.
Gross Margin for the full year ended December 31, 2016
was 66.5%, compared to a gross margin of 64.1% for the same period in 2015. Gross margins were positively affected by strong sales
of the higher priced, higher margin SRT-100 Vision systems.
Selling and Marketing Expenses for the full year ended
December 31, 2016 were $4.92 million, compared to $3.75 million for the same period in 2015. This increase was the result of increased
headcount of the sales team as well as increased advertising and other marketing costs.
General and Administrative Expenses for the full year
ended December 31, 2016 were $3.47 million, compared to $1.59 million for the same period in 2015. This increase was primarily
due to stock compensation expense and other expenses attributable to becoming a public company in June 2016.
Research and Development Expenses for the full year ended
December 31, 2016 were $1.82 million, compared to $1.47 million for the same period in 2015. This increase was primarily due to
new research projects that began in Q4 2016 that are expected to continue throughout 2017.
GAAP Net Loss Attributable to Common Stockholders for
the full year ended December 31, 2016 was ($0.35) million, or ($0.03) per share, compared to a net loss attributable to common
stockholders of ($0.75) million, or ($0.08) per share for the same period in 2015. The net loss attributable to common stockholders
for the full year ended December 31, 2015 included a non-cash accounting charge of approximately $0.51 million for a preferential
distribution attributable to preferred shareholders prior to the IPO.
Adjusted EBITDA for the full year ended December 31,
2016 was $0.81 million, compared to adjusted EBITDA of $0.10 million for the same period in 2015. Adjusted EBITDA is defined as
earnings before depreciation and amortization, income taxes, interest expense, stock compensation expense and litigation settlement
expense. Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the specific reasons these non-GAAP
financial measures are provided.
Conference Call and Webcast Information
Sensus Healthcare's fourth quarter and full year 2016
conference call and webcast will be held at 4:30 pm Eastern Time on Thursday, February 2, 2017 and will feature remarks by Joseph
Sardano, President and CEO, and Arthur Levine, CFO.
The dial-in numbers for the conference
call are 1-877-870-4263 (Toll Free), 1-412-317-0790 (International) and 1-855-669-9657 (Canada Toll Free). Ask the operator to
join you into the Sensus Healthcare Call.
A live webcast of the conference call will be available online
which can be accessed through the Investor Relations section of Sensus Healthcare's website, http://investors.sensushealthcare.com/events-and-presentations.
Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
For interested individuals unable to join
the conference call, a replay of the webcast will remain available on http://investors.sensushealthcare.com/events-and-presentations
for 30 days following the call.
Sensus Healthcare, Inc. is a medical device company that is
committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary
low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated
research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices,
the SRT-100 and SRT-100 Vision . To date, the SRT technology has been used to effectively and safely treat oncological
and non-oncological skin conditions in thousands of patients. For more information, visit http://www.sensushealthcare.com.
Use of Non-GAAP Financial Information
This press release contains supplemental financial information
determined by methods other than in accordance with accounting principles generally accepted in the United States of America ("GAAP").
Sensus Healthcare's management uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis of performance. Adjusted
EBITDA should not be considered a substitute for GAAP basis measures nor should it be viewed as a substitute for operating results
determined in accordance with GAAP Management believes the presentation of Adjusted EBITDA, which excludes the impact of interest
expense, income taxes, depreciation, amortization, stock compensation expense, and litigation settlement expense, provides useful
supplemental information that is essential to a proper understanding of the financial results of Sensus Healthcare. Non-GAAP financial
measures are not formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus
Healthcare. As a complement to GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the